260 related articles for article (PubMed ID: 31357161)
1. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review.
Yang C; Wardenaar KJ; Bosker FJ; Li J; Schoevers RA
J Affect Disord; 2019 Oct; 257():640-649. PubMed ID: 31357161
[TBL] [Abstract][Full Text] [Related]
2. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
Psychiatry Res; 2018 Nov; 269():207-211. PubMed ID: 30153598
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
Sukhram SD; Yilmaz G; Gu J
Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
[TBL] [Abstract][Full Text] [Related]
4. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.
Bekhbat M; Chu K; Le NA; Woolwine BJ; Haroon E; Miller AH; Felger JC
Psychoneuroendocrinology; 2018 Dec; 98():222-229. PubMed ID: 30249443
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis.
Bavaresco DV; Uggioni MLR; Ferraz SD; Marques RMM; Simon CS; Dagostin VS; Grande AJ; da Rosa MI
Pharmacol Biochem Behav; 2020 Jan; 188():172838. PubMed ID: 31837338
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
[No Abstract] [Full Text] [Related]
7. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.
Kiraly DD; Horn SR; Van Dam NT; Costi S; Schwartz J; Kim-Schulze S; Patel M; Hodes GE; Russo SJ; Merad M; Iosifescu DV; Charney DS; Murrough JW
Transl Psychiatry; 2017 Mar; 7(3):e1065. PubMed ID: 28323284
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory profiles of severe treatment-resistant depression.
Strawbridge R; Hodsoll J; Powell TR; Hotopf M; Hatch SL; Breen G; Cleare AJ
J Affect Disord; 2019 Mar; 246():42-51. PubMed ID: 30578945
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
Yang C; Bosker FJ; Li J; Schoevers RA
BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
[TBL] [Abstract][Full Text] [Related]
10. Connection between inflammatory markers, antidepressants and depression.
Crnković D; Buljan D; Karlović D; Krmek M
Acta Clin Croat; 2012 Mar; 51(1):25-33. PubMed ID: 22919999
[TBL] [Abstract][Full Text] [Related]
11. Effect of recombinant erythropoietin on inflammatory markers in patients with affective disorders: A randomised controlled study.
Vinberg M; Weikop P; Olsen NV; Kessing LV; Miskowiak K
Brain Behav Immun; 2016 Oct; 57():53-57. PubMed ID: 27181179
[TBL] [Abstract][Full Text] [Related]
12. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Medeiros da Frota Ribeiro C; Riva-Posse P
Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
[TBL] [Abstract][Full Text] [Related]
13. Cytokine- and Vascular Endothelial Growth Factor-Related Gene-Based Genome-Wide Association Study of Low-Dose Ketamine Infusion in Patients with Treatment-Resistant Depression.
Tsai SJ; Kao CF; Su TP; Li CT; Lin WC; Hong CJ; Bai YM; Tu PC; Chen MH
CNS Drugs; 2023 Mar; 37(3):243-253. PubMed ID: 36763263
[TBL] [Abstract][Full Text] [Related]
14. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
Kang MJY; Vazquez GH
J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
[TBL] [Abstract][Full Text] [Related]
15. Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.
Rong C; Park C; Rosenblat JD; Subramaniapillai M; Zuckerman H; Fus D; Lee YL; Pan Z; Brietzke E; Mansur RB; Cha DS; Lui LMW; McIntyre RS
Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29673146
[TBL] [Abstract][Full Text] [Related]
16. Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression.
Bot M; Carney RM; Freedland KE; Rubin EH; Rich MW; Steinmeyer BC; Mann DL
J Psychosom Res; 2011 Jul; 71(1):13-7. PubMed ID: 21665007
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder.
Haroon E; Daguanno AW; Woolwine BJ; Goldsmith DR; Baer WM; Wommack EC; Felger JC; Miller AH
Psychoneuroendocrinology; 2018 Sep; 95():43-49. PubMed ID: 29800779
[TBL] [Abstract][Full Text] [Related]
18. Interleukin, tumor necrosis factor-α and C-reactive protein profiles in melancholic and non-melancholic depression: A systematic review.
Yang C; Tiemessen KM; Bosker FJ; Wardenaar KJ; Lie J; Schoevers RA
J Psychosom Res; 2018 Aug; 111():58-68. PubMed ID: 29935756
[TBL] [Abstract][Full Text] [Related]
19. Effects of antidepressant drug therapy with or without physical exercise on inflammatory biomarkers in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials.
Fernandes BM; Scotti-Muzzi E; Soeiro-de-Souza MG
Eur J Clin Pharmacol; 2022 Mar; 78(3):339-349. PubMed ID: 34708271
[TBL] [Abstract][Full Text] [Related]
20. D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression.
Moaddel R; Luckenbaugh DA; Xie Y; Villaseñor A; Brutsche NE; Machado-Vieira R; Ramamoorthy A; Lorenzo MP; Garcia A; Bernier M; Torjman MC; Barbas C; Zarate CA; Wainer IW
Psychopharmacology (Berl); 2015 Jan; 232(2):399-409. PubMed ID: 25056852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
